Chapter 14

Therapeutic HPV Vaccines: Immunogenicity, Efficacy and Safety

Azam Bolhassani

Abstract

Up to now, a large number of HPV therapeutic vaccines have been developed targeting E6 and E7 oncoproteins including peptide/protein-based vaccines, live vector vaccines, cell-based vaccines and nucleic acid-based vaccines; each with advantages and disadvantages. These vaccines control HPV infection through cellmediated immunity in preclinical and clinical trials, e.g., adoptive T-cell therapy in patients with advanced cervical cancer and/or DNA-based vaccine in HPV-16 or HPV- 18 positive CIN clinical trials. In this chapter, the potential use of therapeutic vaccines as safe and effective pharmacological tools in cervical diseases will be explained, focusing on vaccines that have been tested in clinical trials.

Total Pages: 182-200 (19)

Purchase Chapter  Book Details

RELATED BOOKS

.COVID 19 – Monitoring with IoT Devices.
.Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents.
.Recent Trends and The Future of Antimicrobial Agents - Part 2.
.COVID-19: Origin, Impact and Management (Part 1).